Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02494479 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis
A Phase 2 study, sponsored by Cellceutix Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT02494479 is a Phase 2 study that has completed, run by Cellceutix Corporation. The registered enrollment target is 115 participants.
The verdict
NCT02494479, a Phase 2 study, has completed, sponsored by Cellceutix Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy and safety of Prurisol using three different oral daily dose regimens administered to subjects with active mild to moderate chronic plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG Prurisol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02494479
The ClinicalTrials.gov registry entry for NCT02494479 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cellceutix Corporation, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02494479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02494479 about?
NCT02494479 is a clinical study titled "Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis". This study is designed to evaluate the efficacy and safety of Prurisol using three different oral daily dose regimens administered to subjects with active mild to moderate chronic plaque psoriasis.
What is the current status of trial NCT02494479?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2015-08. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02494479?
The interventions under investigation include: Placebo (DRUG), Prurisol (DRUG).
Who is sponsoring clinical trial NCT02494479?
This trial is sponsored by Cellceutix Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.